Verastem, Inc. (NASDAQ: VSTM) shares gained about 6.4% to $8.25 on Wednesday, making it one of the top performers in the PRISM Women’s Health Index….
Key Points Armata announced two issued U.S. patents covering treatment methods involving its investigational bacteriophage candidates, AP-SA02 and AP-PA02. The AP-SA02 patent was issued October…
Key Points Owlet launched a partnership with VillageFor to support new and expecting parents through pregnancy, postpartum and other paths to parenthood. Owlet360 members will…
Key Points Neogen’s fiscal first-quarter revenue rose 6.5% to $222.8 million, with core growth of 8.1%. Adjusted EBITDA increased 17% to $41.6 million, and adjusted…
October 07, 2026
Zura Bio Shares Climb 9% as Hidradenitis Suppurativa Data Takes Center Stage Ahead of Its Q4 Readout
Zura Bio Limited (NASDAQ: ZURA) shares rose about 9.5% to $4.34 on Wednesday, making it the top gainer in the PRISM Biotech Index. The move…
Key Points Enliven Therapeutics reached FDA alignment on the final design of ENABLE-2, its pivotal Phase 3 trial of relcobatinib in previously treated chronic myeloid…
October 07, 2026
The Joint Reclaims Texas Development Rights, Expands Potential for 150-Plus New Clinics
Key Points The Joint reacquired regional developer rights across Dallas, Austin, San Antonio and Houston. Combined with other 2026 territory reacquisitions, the markets represent potential…
October 06, 2026
Kamada Doubles Israeli Biosimilar Lineup, Targets Up to $25 Million in Annual Revenue by 2030
Key Points Kamada launched Ustekinumab-Kamada and Enoxaparin-Kamada in Israel, expanding its marketed biosimilar portfolio from two products to four. Ustekinumab-Kamada references Stelara, while Enoxaparin-Kamada references…
Key Points Telix administered the first U.S. commercial doses of Pixclara at medical centers in Indianapolis and Cleveland. Pixclara is the only FDA-approved radiopharmaceutical imaging…
Key Points Amylyx will present Phase 3 LUCIDITY topline results for avexitide at ObesityWeek 2026 on November 15. The company previously announced positive topline results…
Key Points OKYO Pharma enrolled the first patients in NEPTUNE, its pivotal Phase 3 trial of urcosimod for neuropathic corneal pain. Melissa Toyos enrolled the…
Key Points Korro Bio dosed the first healthy-volunteer cohort in ANCHOR, its Phase 1/2 trial of KRRO-121. Participants in the first cohort received a single…